Skip to content
Peptigraph home

Sermorelin Half-Life: How Long It Stays in Your System

How long Sermorelin stays in the body, how that shapes dosing frequency, and what is known about drug testing.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureGHRH analogUpdated
Half-life
Not found
No published half-life found (PubMed search, 11 Oct 2026)
Dosing interval
Varies by study
as used in studies
WADA
Prohibited (S2.2.4)
In and out of competition
Detection window
2 findings
from anti-doping studies, below

Sermorelin half-life

Half-life: no published half-life found (PubMed search, 11 Oct 2026). A half-life depends on the route (under the skin, into a vein, by mouth or nasal spray), so we report it per route with the study it came from.

What half-life means

Half-life is the time it takes for the amount of a drug in the blood to fall by half. After one half-life, about 50% is left; after two, about 25%; after four to five, only a few percent remain.

  • A long half-life lets a drug be dosed less often, for example once a week.
  • A short half-life means levels rise and fall quickly, which is why some peptides are given daily or more often.
  • Effects can outlast blood levels, so half-life alone does not tell you how long a drug works.

What it means for dosing frequency

Dosing intervals used in published studies of Sermorelin:

Changing the interval changes how much drug builds up between doses, so it is not a free choice.

Drug tests and sport

Prohibited by WADA (S2.2.4)

Sermorelin is named as a GHRH analogue in S2.2.4 (growth hormone releasing factors), prohibited at all times.

Detection findings from anti-doping analytical studies:

  • A urine assay detects CJC-1295 and other GHRH analogues at very low concentrations. · PMID 35298973
  • Labs expect GHRH analogues like CJC-1295 to be hard to find because of tiny urine concentrations; the study reports no detections in routine anti-doping samples. · PMID 34665524

Tested athletes should treat it as prohibited (s2.2.4) at all times.

Laboratory half-lives of the sequence sermorelin comes from

In porcine plasma in vitro, GRF(1-29)-NH2 broke down with a t1/2 of 13 min.[12]

Substituting Gly15 with Ala15 slightly prolonged that plasma half-life, to 17 min.[12]

A separate rat study of GRF amide gave apparent half-lives of 18 min in rat serum and 13 min in liver homogenate.[13]

No human sermorelin figure is cached

The only FDA record is Geref, marked discontinued, so there is no marketed label whose pharmacokinetics section could be quoted.[14]

WADA's prohibited list names sermorelin as an example of a GHRH analogue.[1]

Common questions

How long does Sermorelin stay in your system?

We found no published half-life for Sermorelin (PubMed search, 11 Oct 2026). As a rule, most of a dose is cleared after about four to five half-lives.

What is the half-life of sermorelin?

No human value is cached; the nearest figure is 13 min for GRF(1-29)-NH2 in porcine plasma in vitro.[12]

Is Sermorelin on the WADA prohibited list?

Yes. Prohibited by WADA (S2.2.4).

Does sermorelin show up on a drug test?

Sermorelin is a named substance on WADA's prohibited list. The cached sources say nothing about workplace drug panels.[1]

Is sermorelin on the WADA list?

Yes. WADA's list names sermorelin as a GHRH analogue.[1]

More on Sermorelin

Sources

  1. 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  2. 2An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
  3. 3Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
  4. 4Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men.The Journal of clinical endocrinology and metabolism · 1992PMID 1379256Accessed 2 Oct 2026
  5. 5Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels.American journal of men's health · 2017PMID 28830317Accessed 2 Oct 2026
  6. 6Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.Metabolism: clinical and experimental · 1997PMID 9005976Accessed 2 Oct 2026
  7. 7Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group.The Journal of clinical endocrinology and metabolism · 1996PMID 8772599Accessed 2 Oct 2026
  8. 8PubMed search: (sermorelin[tiab] OR Geref[tiab]) (34 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  9. 9PubMed search: (sermorelin[tiab] OR "GHRH(1-29)"[tiab] OR "GRF(1-29)"[tiab] OR "GHRH 1-29"[tiab]) AND (elderly[tiab] OR aging[tiab] OR "older adults"[tiab] OR adults[tiab]) AND (treatment[tiab] OR therapy[tiab] OR administration[tiab]) (15 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  10. 10PubMed search: (sermorelin[tiab] OR Geref[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  11. 11PubMed search: (sermorelin[tiab] OR Geref[tiab] OR "GHRH(1-29)"[tiab] OR "GRF(1-29)"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (21 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  12. 12In vitro stability of growth hormone releasing factor (GRF) analogs in porcine plasma.Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme · 1991PMID 1826667Accessed 5 Oct 2026
  13. 13Catabolism of rat growth hormone-releasing factor(1-29) amide in rat serum and liver.Peptides · 1992PMID 1437711Accessed 5 Oct 2026
  14. 14Drugs@FDA (openFDA) search: active ingredient "sermorelin"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026

Found an error? Report a correction.